Mucormycosis is an opportunistic infection affecting mainly immunocompromised hosts. Infection in immunocompetent patients is rare, but may occur typically in trauma or burn victims. We report on a previously healthy young man suffering devastating trauma from an agricultural accident with the subsequent development of a multifocal mucormycosis. Diagnosis was achieved by cultures obtained from non-healing wounds, some of them even covered by a macroscopic mold formation. Specific treatment was initiated soon after the preliminary results indicated mucormycosis. Aggressive surgical therapy, with concomitant use of systemic posaconazole and topical amphotericin B in a combination treatment, led to the elimination of the fungal infection. The remaining deep tissue defects were consequently reconstructed by a muscle flap and skin graft autotransplantation with a good overall outcome, which would not have been possible without the complete remission of mucormycosis. This case study presents the successful use of a combination treatment with systemic posaconazole and topical amphotericin B and underlines the importance of timely and aggressive surgical therapy.

Department of Anesthesiology and Intensive Care Medicine Faculty of Medicine Masaryk University and University Hospital 625 00 Brno Czech Republic

Zobrazit více v PubMed

Skiada A., Lass-Floerl C., Klimko N., Ibrahim A., Roilides E., Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med. Mycol. 2018;56:93–101. doi: 10.1093/mmy/myx101. PubMed DOI PMC

Mitchell T.A., Hardin M.O., Murray C.K., Ritchie J.D., Cancio L.C., Renz E.M., White C.E. Mucormycosis attributed mortality: A seven-year review of surgical and medical management. Burns. 2014;408:1689–1695. doi: 10.1016/j.burns.2014.03.013. PubMed DOI

Dang J., Goel P., Choi K.J., Massenzio E., Landau M.J., Pham C.H., Huang S., Yenikomshian H.A., Spellberg B., Gillenwater T.J. Mucormycosis following burn injuries: A systematic review. Burns. 2023;49:15–25. doi: 10.1016/j.burns.2022.05.012. PubMed DOI

Petrikkos G., Skiada A., Lortholary O., Roilides E., Walsh T.J., Kontoyiannis D.P. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 2012;54:S23–S34. doi: 10.1093/cid/cir866. PubMed DOI

Cornely O.A., Alastruey-Izquierdo A., Arenz D., Chen S.C.A., Dannaoui E., ECMM MSG Global Guideline Writing Group Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019;19:e405–e421. doi: 10.1016/S1473-3099(19)30312-3. PubMed DOI PMC

Akers K.S., Rowan M.P., Niece K.L., Graybill J.C., Mende K., Chung K.K., Murray C.K. Antifungal wound penetration of amphotericin and voriconazole in combat-related injuries: Case report. BMC Infect. Dis. 2015;15:184. doi: 10.1186/s12879-015-0918-8. PubMed DOI PMC

Borman A.M., Fraser M., Patterson Z., Palmer M.D., Johnson E.M. In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles. J. Fungi. 2021;2:271. doi: 10.3390/jof7040271. PubMed DOI PMC

Deray G. Amphotericin B nephrotoxicity. J. Antimicrob. Chemother. 2002;49:37–41. doi: 10.1093/jac/49.suppl_1.37. PubMed DOI

Brunet K., Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. J. Mycol. Med. 2020;30:101007. doi: 10.1016/j.mycmed.2020.101007. PubMed DOI

Marty F.M., Ostrosky-Zeichner L., Cornely O.A., Mullane K.M., Perfect J.R., Thompson G.R., 3rd, Alangaden G.J., Brown J.M., Fredricks D.N., Heinz W.J., et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect. Dis. 2016;16:828–837. doi: 10.1016/S1473-3099(16)00071-2. PubMed DOI

Kyvernitakis A., Torres H.A., Jiang Y., Chamilos G., Lewis R.E., Kontoyiannis D.P. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: A propensity score analysis. Clin. Microbiol. Infect. 2016;22:e1–e8. doi: 10.1016/j.cmi.2016.03.029. PubMed DOI